Literature DB >> 32728799

18F-FDG brain PET hypometabolism in post-SARS-CoV-2 infection: substrate for persistent/delayed disorders?

E Guedj1, M Million2,3, P Dudouet2,4, H Tissot-Dupont2, F Bregeon2,3,5, S Cammilleri6, D Raoult2,3.   

Abstract

PURPOSE: Several brain complications of SARS-CoV-2 infection have been reported. It has been moreover speculated that this neurotropism could potentially cause a delayed outbreak of neuropsychiatric and neurodegenerative diseases of neuroinflammatory origin. A propagation mechanism has been proposed across the cribriform plate of the ethmoid bone, from the nose to the olfactory epithelium, and possibly afterward to other limbic structures, and deeper parts of the brain including the brainstem.
METHODS: Review of clinical examination, and whole-brain voxel-based analysis of 18F-FDG PET metabolism in comparison with healthy subjects (p voxel < 0.001, p-cluster < 0.05, uncorrected), of two patients with confirmed diagnosis of SARS-CoV-2 explored at the post-viral stage of the disease.
RESULTS: Hypometabolism of the olfactory/rectus gyrus was found on the two patients, especially one with 4-week prolonged anosmia. Additional hypometabolisms were found within amygdala, hippocampus, parahippocampus, cingulate cortex, pre-/post-central gyrus, thalamus/hypothalamus, cerebellum, pons, and medulla in the other patient who complained of delayed onset of a painful syndrome.
CONCLUSION: These preliminary findings reinforce the hypotheses of SARS-CoV-2 neurotropism through the olfactory bulb and the possible extension of this impairment to other brain structures. 18F-FDG PET hypometabolism could constitute a cerebral quantitative biomarker of this involvement. Post-viral cohort studies are required to specify the exact relationship between such hypometabolisms and the possible persistent disorders, especially involving cognitive or emotion disturbances, residual respiratory symptoms, or painful complaints.

Entities:  

Keywords:  18F-FDG-PET; Anosmia; Brainstem; COVID-19; Functional disorders; Limbic system; SARS-CoV-2

Mesh:

Substances:

Year:  2020        PMID: 32728799      PMCID: PMC7391029          DOI: 10.1007/s00259-020-04973-x

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


Several brain complications of SARS-CoV-2 infection have been already reported including acute cerebrovascular disorders, encephalopathy, encephalitis, and Guillain-Barré syndromes [1]. It has been moreover speculated that SARS-CoV-2 neurotropism could potentially cause a delayed outbreak with onset and progression of neuropsychiatric and neurodegenerative diseases of neuroinflammatory origin [2]. A recent systematic review and meta-analysis of other coronavirus infections confirms confusion, depressed mood, anxiety, impaired memory, or insomnia in 27.9 to 41.9% of patients in the acute illness, while in the post-illness stage, the prevalence of post-traumatic stress disorder was of 32.2%, and almost 15% for depression and anxiety disorders [3], with also a clinical overlap with fibromyalgia and chronic fatigue syndrome [4]. As previously shown for other SARS-CoV infections, a propagation mechanism has been proposed across the cribriform plate of the ethmoid bone, from the nose to the olfactory epithelium where ACE2 receptors are highly expressed [5]. This viral neurotropism through the olfactory bulb could be especially responsible of the anosmia frequently reported in these patients [5]. Accordingly, a cortical FLAIR-MRI hyperintensity was visually identified in the right gyrus rectus and olfactory bulb of a patient with SARS-CoV-2 anosmia [6]. By trans-synaptic transfer, again already reported for other virus [7], this propagation from the olfactory bulb could spread to other limbic structures, such as the amygdala, the hippocampus, and the cingulate cortex which are well known to be involved in cognition and emotion [8] and pathologically in neurodegenerative and neuropsychiatric diseases [2]. SARS-CoV-2 may also target deeper parts of the brain including the thalamus and the brainstem and then potentially contributes to the respiratory impairment [7] and also to painful symptoms. We report here the clinical case of two patients with confirmed diagnosis of SARS-CoV-2, which were explored by whole-body 18F-FDG PET in the post-illness stage to metabolically characterize residual lung abnormalities. Brain PET metabolism was statistically analyzed in comparison with healthy subjects at whole-brain voxel-based level (proportional scaling; p voxel < 0.001, p-cluster < 0.05, uncorrected; healthy subjects of same median age as the patient around a ± 10-year range), and findings were confronted to the hypothesis of the propagation of SARS-Co-2 from the olfactory bulb to other limbic structures and possibly the brainstem.

Case reports

We first report the case of a 54-year-old man with a SARS-CoV-2 confirmed by nasopharyngeal swab. Type 2 diabetes, hypertension, and minor asthma were found in his past medical history. The pneumonia was complicated with a severe acute respiratory distress syndrome requiring 6 days of mechanical ventilation and 15 days of hospitalization in intensive care unit. The evolution was clinically favorable, with nevertheless the persistence of anosmia and ageusia during 4 additional weeks and delayed occurrence of memory complaints 8 weeks after the first pulmonary symptoms. A whole-body 18F-FDG PET was afterward performed, while the patients only complained of memory impairment, to evaluate the metabolic activity of persistent pulmonary CT condensations. No suspect lung hypermetabolism was found. The brain 18F-FDG PET exhibited hypometabolism of bilateral rectal gyrus prevailing on the right side, without evident abnormality on the attenuation correction CT scan. A whole-brain voxel-based SPM8 comparison, to a local database of 23 healthy subjects selected on the same median age as the patient (range of ± 10 years around the age of the patient; mean age, 54.4 years old; standard deviation, 6.7 years), confirms hypometabolism of the right olfactory/rectal gyrus, with interestingly no remote abnormalities to point toward another brain gateway (Fig. 1; p voxel < 0.001, p-cluster < 0.05, uncorrected; Table 1).
Fig. 1

Brain 18F-FDG PET hypometabolism of the first patient. Bilateral hypometabolism of olfactory/rectal gyrus is visually identified (white arrow), and confirmed by whole-brain voxel-based SPM8 comparison, to healthy subjects (p voxel < 0.001, p-cluster < 0.05, uncorrected)

Table 1

Main 18F-FDG PET hypometabolic findings for each patient in comparison to healthy subjects (p voxel < 0.001, p-cluster < 0.05, uncorrected)

ClusterClusterVoxelvoxelTalairach coordinatesLocalization
kp valueT scorep valuexyz
Case 12860.0235.97< 0.0014.030.0− 27.0Right rectal gyrus (BA11)
Case 23574< 0.001*6.92< 0.001*− 22.0− 37.0− 2.0Left hippocampus
6.64< 0.001*− 18.0− 43.0− 3.0Left parahippocampal gyrus (BA19)
5.39< 0.001− 18.0− 16.0− 13.0Left parahippocampal gyrus (BA28)
5.27< 0.00120.0− 26.0− 9.0Right parahippocampal gyrus (BA28)
4.70< 0.001− 8.0− 50.04.0Left cerebellar anterior lobe
4.58< 0.001− 6.0− 6.0− 3.0Hypothalamus
4.48< 0.001− 6.0− 16.0− 1.0Left thalamus
4.35< 0.00118.03.0− 17.0Right parahippocampal gyrus (BA34)
4.30< 0.00124.05.0− 19.0Right uncus (BA28)
4.29< 0.00126.0− 37.0− 3.0Right hippocampus
4.18< 0.0016.020.0− 25.0Right rectal gyrus (BA11)
4.13< 0.0012.0− 32.0− 22.0Right cerebellar culmen
6040.001*5.87< 0.001− 4.0− 31.0− 40.0Medulla
3.79< 0.00118.0− 34.0− 29.0Pons
3.710.00112.0− 35.0− 40.0Right cerebellar tonsil
5870.001*5.29< 0.001− 4.0− 12.037.0Left cingulate gyrus (BA24)
3.91< 0.001− 10.0− 43.033.0Left cingulate gyrus (BA31)
3900.007*5.08< 0.00159.0− 1.013.0Right pre-central gyrus (BA6)
4.91< 0.00161.0− 23.014.0Right post-central gyrus (BA40)
4.48< 0.00163.0− 36.015.0Right superior temporal gyrus (BA22)

The k value represents the number of voxels inside a particular cluster. p values are all presented as uncorrected for multiple comparisons. p values still significant at p < 0.05 after correction for multiple comparisons using FWE method (family-wise error) are indicated with *. Talairach coordinates are expressed in mm. BA Brodmann Area

Brain 18F-FDG PET hypometabolism of the first patient. Bilateral hypometabolism of olfactory/rectal gyrus is visually identified (white arrow), and confirmed by whole-brain voxel-based SPM8 comparison, to healthy subjects (p voxel < 0.001, p-cluster < 0.05, uncorrected) Main 18F-FDG PET hypometabolic findings for each patient in comparison to healthy subjects (p voxel < 0.001, p-cluster < 0.05, uncorrected) The k value represents the number of voxels inside a particular cluster. p values are all presented as uncorrected for multiple comparisons. p values still significant at p < 0.05 after correction for multiple comparisons using FWE method (family-wise error) are indicated with *. Talairach coordinates are expressed in mm. BA Brodmann Area We secondly report the case of a 62-year-old man with a SARS-CoV-2 pneumonia confirmed by nasopharyngeal swab. The patient had not significant antecedent. The pneumonia was complicated with moderate acute respiratory distress syndrome requiring 24-h hospitalization in intensive care unit and treatment by low-flow nasal oxygen. The patient never experienced anosmia or ageusia. The evolution was clinically favorable with nevertheless the occurrence, 7 days after the first pulmonary symptoms, of sensitive lower leg crushing sensation alternating in right/left toes, without any motor or sensory deficiency on clinical examination. The hypothesis of peripheral involvement is still in investigation. A whole-body 18F-FDG PET was afterwards performed, while the patients only complained of this painful syndrome, to evaluate the metabolic activity of persistent pulmonary CT condensations. No suspect lung hypermetabolism was found. The brain 18F-FDG PET exhibited extended bilateral marked hypometabolism especially involving olfactory/rectal gyrus, other limbic structures such as amygdala, hippocampus, parahippocampus and cingulate cortex, as well as the right pre-/post-central gyrus, the right superior temporal gyrus, bilateral thalamus, hypothalamus, cerebellum, pons and medulla. These hypometabolisms are found on a whole-brain voxel-based SPM8 comparison with a local database of 24 healthy subjects selected on the same median age as the patient (range of ± 10 years around the age of the patient; mean age, 62.2 years old; standard deviation, 7.0 years) (Fig. 2; p voxel < 0.001, p-cluster < 0.05, uncorrected; Table 1). No abnormality was found on the attenuation correction CT scan.
Fig. 2

Brain 18F-FDG PET hypometabolism of the second patient. Bilateral hypometabolism of olfactory/rectal gyrus (white arrow), medial temporal lobe (white*), and brainstem (white+) is visually identified, and confirmed by whole-brain voxel-based SPM8 comparison to healthy subjects (p voxel < 0.001, p-cluster < 0.05, uncorrected), also including the right pre-/post-central gyrus, the right superior temporal gyrus, bilateral thalamus, hypothalamus, and cerebellum

Brain 18F-FDG PET hypometabolism of the second patient. Bilateral hypometabolism of olfactory/rectal gyrus (white arrow), medial temporal lobe (white*), and brainstem (white+) is visually identified, and confirmed by whole-brain voxel-based SPM8 comparison to healthy subjects (p voxel < 0.001, p-cluster < 0.05, uncorrected), also including the right pre-/post-central gyrus, the right superior temporal gyrus, bilateral thalamus, hypothalamus, and cerebellum

Discussion

These preliminary findings reinforce the hypotheses of SARS-CoV-2 neurotropism through the olfactory bulb in patients with or without anosmia, and the possible extension of this impairment to other limbic structures as well as to the pre-/post-central gyrus, the thalamus/hypothalamus, the cerebellum and the brainstem, with brain abnormalities persisting after the remission of the infectious phase. 18F-FDG PET hypometabolism could constitute a cerebral quantitative biomarker of this involvement [9]. Post-viral cohort studies with longer follow-up are required to specify the exact relationship between such hypometabolisms and the possible persistent disorders, especially involving cognitive or emotion disturbances, residual respiratory symptoms, or painful complaints. More earlier brain PET studies could also investigate the possible transition between hyper- and hypo-metabolisms in these patients. These metabolic features could be also correlated to other brain PET biomarkers of neuroinflammation and infection, such as TSPO and CXCR4 expressions [10], and also to the impact of anti-inflammatory therapeutics, to address the possible relationship with the hypothesized association to neuropsychiatric and neurodegenerative diseases of neuroinflammatory origin [2].
  10 in total

Review 1.  The anatomical connections of the macaque monkey orbitofrontal cortex. A review.

Authors:  C Cavada; T Compañy; J Tejedor; R J Cruz-Rizzolo; F Reinoso-Suárez
Journal:  Cereb Cortex       Date:  2000-03       Impact factor: 5.357

Review 2.  Infection and Inflammation Imaging: Beyond FDG.

Authors:  Malte Kircher; Constantin Lapa
Journal:  PET Clin       Date:  2020-02-11

3.  Magnetic Resonance Imaging Alteration of the Brain in a Patient With Coronavirus Disease 2019 (COVID-19) and Anosmia.

Authors:  Letterio S Politi; Ettore Salsano; Marco Grimaldi
Journal:  JAMA Neurol       Date:  2020-08-01       Impact factor: 18.302

4.  Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study.

Authors:  Harvey Moldofsky; John Patcai
Journal:  BMC Neurol       Date:  2011-03-24       Impact factor: 2.474

5.  Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic.

Authors:  Jonathan P Rogers; Edward Chesney; Dominic Oliver; Thomas A Pollak; Philip McGuire; Paolo Fusar-Poli; Michael S Zandi; Glyn Lewis; Anthony S David
Journal:  Lancet Psychiatry       Date:  2020-05-18       Impact factor: 27.083

Review 6.  Impact of SARS-CoV-2 infection on neurodegenerative and neuropsychiatric diseases: a delayed pandemic?

Authors:  P J Serrano-Castro; G Estivill-Torrús; P Cabezudo-García; J A Reyes-Bueno; N Ciano Petersen; M J Aguilar-Castillo; J Suárez-Pérez; M D Jiménez-Hernández; M Á Moya-Molina; B Oliver-Martos; C Arrabal-Gómez; F Rodríguez de Fonseca
Journal:  Neurologia (Engl Ed)       Date:  2020-04-17

7.  Is the Collapse of the Respiratory Center in the Brain Responsible for Respiratory Breakdown in COVID-19 Patients?

Authors:  Sonu Gandhi; Amit Kumar Srivastava; Upasana Ray; Prem Prakash Tripathi
Journal:  ACS Chem Neurosci       Date:  2020-04-29       Impact factor: 4.418

8.  PET imaging of COVID-19: the target and the number.

Authors:  E Guedj; A Verger; S Cammilleri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-04-17       Impact factor: 9.236

9.  Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms.

Authors:  Abdul Mannan Baig; Areeba Khaleeq; Usman Ali; Hira Syeda
Journal:  ACS Chem Neurosci       Date:  2020-03-13       Impact factor: 4.418

10.  Neurologic Features in Severe SARS-CoV-2 Infection.

Authors:  Julie Helms; Stéphane Kremer; Hamid Merdji; Raphaël Clere-Jehl; Malika Schenck; Christine Kummerlen; Olivier Collange; Clotilde Boulay; Samira Fafi-Kremer; Mickaël Ohana; Mathieu Anheim; Ferhat Meziani
Journal:  N Engl J Med       Date:  2020-04-15       Impact factor: 91.245

  10 in total
  51 in total

1.  Associations of Depression, Anxiety, Worry, Perceived Stress, and Loneliness Prior to Infection With Risk of Post-COVID-19 Conditions.

Authors:  Siwen Wang; Luwei Quan; Jorge E Chavarro; Natalie Slopen; Laura D Kubzansky; Karestan C Koenen; Jae Hee Kang; Marc G Weisskopf; Westyn Branch-Elliman; Andrea L Roberts
Journal:  JAMA Psychiatry       Date:  2022-09-07       Impact factor: 25.911

Review 2.  Potential of Endogenous Oxytocin in Endocrine Treatment and Prevention of COVID-19.

Authors:  Stephani C Wang; Fengmin Zhang; Hui Zhu; Haipeng Yang; Yang Liu; Ping Wang; Vladimir Parpura; Yu-Feng Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-03       Impact factor: 6.055

Review 3.  Olfactory and gustatory disorders in COVID-19.

Authors:  Ludger Klimek; Jan Hagemann; Julia Döge; Laura Freudelsperger; Mandy Cuevas; Felix Klimek; Thomas Hummel
Journal:  Allergo J Int       Date:  2022-06-20

Review 4.  Positron emission tomography in the COVID-19 pandemic era.

Authors:  Chentao Jin; Xiaoyun Luo; Shufang Qian; Kai Zhang; Yuanxue Gao; Rui Zhou; Peili Cen; Zhoujiao Xu; Hong Zhang; Mei Tian
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-05-19       Impact factor: 10.057

5.  Collicular Hyperactivation in Patients with COVID-19: A New Finding on Brain MRI and PET/CT.

Authors:  A Chammas; C Bund; F Lersy; J-C Brisset; F-D Ardellier; S Kremer; I J Namer
Journal:  AJNR Am J Neuroradiol       Date:  2021-05-20       Impact factor: 4.966

6.  Molecular Imaging Findings on Acute and Long-Term Effects of COVID-19 on the Brain: A Systematic Review.

Authors:  Philipp T Meyer; Sabine Hellwig; Ganna Blazhenets; Jonas A Hosp
Journal:  J Nucl Med       Date:  2022-02-17       Impact factor: 11.082

7.  SARS-CoV-2 is associated with changes in brain structure in UK Biobank.

Authors:  Gwenaëlle Douaud; Soojin Lee; Fidel Alfaro-Almagro; Christoph Arthofer; Chaoyue Wang; Paul McCarthy; Frederik Lange; Jesper L R Andersson; Ludovica Griffanti; Eugene Duff; Saad Jbabdi; Bernd Taschler; Peter Keating; Anderson M Winkler; Rory Collins; Paul M Matthews; Naomi Allen; Karla L Miller; Thomas E Nichols; Stephen M Smith
Journal:  Nature       Date:  2022-03-07       Impact factor: 69.504

Review 8.  COVID-19 imaging: Diagnostic approaches, challenges, and evolving advances.

Authors:  Dante L Pezzutti; Vibhor Wadhwa; Mina S Makary
Journal:  World J Radiol       Date:  2021-06-28

9.  Heterogeneity in Regional Damage Detected by Neuroimaging and Neuropathological Studies in Older Adults With COVID-19: A Cognitive-Neuroscience Systematic Review to Inform the Long-Term Impact of the Virus on Neurocognitive Trajectories.

Authors:  Riccardo Manca; Matteo De Marco; Paul G Ince; Annalena Venneri
Journal:  Front Aging Neurosci       Date:  2021-06-03       Impact factor: 5.750

10.  Clinical characterization of dysautonomia in long COVID-19 patients.

Authors:  Nicolas Barizien; Morgan Le Guen; Stéphanie Russel; Pauline Touche; Florent Huang; Alexandre Vallée
Journal:  Sci Rep       Date:  2021-07-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.